Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14143222 | 0.84 | MAPT (0.44) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL3896447 | 0.83 | ERCC5 (0.46) | ERCC5FEN1PIK3CAPARP1MEN1 | |
| SCHEMBL5205328 | 0.83 | GABRP (0.55) | ERCC5FEN1PIK3CAPARP1MEN1 | |
| SCHEMBL5790783 | 0.82 | PIK3CA (0.45) | PIK3CAMEN1KMT2AALDH1A1LMNA | |
| Bromide SCHEMBL6992895 | 0.82 | ERCC5 (0.44) | ERCC5FEN1PIK3CAPARP1MEN1 | |
| SCHEMBL3284705 | 0.81 | KDM4E (0.52) | ERCC5FEN1PARP1MEN1KMT2A | |
| SCHEMBL5787643 | 0.79 | CES2 (0.42) | PIK3CAVNN1KCNQ3KCNQ2KCNQ5 | |
| SCHEMBL5200968 | 0.77 | JAK2 (0.53) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL30511470 | 0.76 | MAPT (0.66) | ERCC5FEN1PIK3CAPARP1MEN1 | |
| SCHEMBL31405561 | 0.76 | ERCC5 (0.56) | ERCC5FEN1PIK3CAPARP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543003-B1 | IMIDAZO¬1,2-A|PYRIDINES | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | DODIC NERINA | 2005-11-03 | — | — | US | disclosed |
| US-20050234029-A1 | Compounds | DODIC NERINA | 2005-10-20 | — | — | US | disclosed |
| EP-1543003-A2 | IMIDAZO[1,2-A]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1539748-A1 | 2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004013138-A2 | IMIDAZO`1,2-A!PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004013135-A1 | 2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | SMAD2, SMAD3, ALK | ERCC5 2313/4885FEN1 3195/4885PIK3CA 369/4885 |
| US-20050234029-A1 | Compounds | SMAD3, SMAD2, ACVR1 | ERCC5 2067/4885FEN1 2804/4885PIK3CA 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.